Pentoxifylline rescue preserves lung function in isolated canine lungs injured with phorbol myristate acetate.
OBJECTIVE
We hypothesized that pentoxifylline, administered after phorbol myristate acetate (PMA), would diminish the severity of lung injury.


METHODS
Animal research laboratory.


METHODS
Comparative study.


METHODS
Mongrel dogs (n = 33).


METHODS
Baseline measurements were obtained from the isolated blood-perfused dog lung lobes after 1 h of stable perfusion and ventilation. Four different measures of lung compliance were obtained along with WBC and neutrophil counts. Pulmonary vascular resistance (PVR) and capillary filtration coefficient (Kf) were calculated, and the ratio of a normalized maximal enzymatic conversion rate to the Michaelis-Menten constant (Amax/Km) was used to assess perfused capillary surface area. The control lobes (n = 8) were ventilated and perfused for an additional 40 min while the injured lobes (n = 17) received PMA (0.1 microg/mL of perfusate). The pentoxifylline-protected lobes (n = 8) were treated with pentoxifylline (1 mg/mL of perfusate) 10 min after injury with PMA. All measurements were then repeated.


RESULTS
The three groups did not differ significantly at baseline. The control lobes remained relatively stable over time. The injured lobes demonstrated marked deterioration in compliance: 8.79 +/- 0.7 to 5.97 +/- 0.59 mL/cm H(2)O (p < 0.05) vs 10.1 +/- 1.0 to 8.07 +/- 0.72 mL/cm H(2)O and 9.6 +/- 1.1 to 9.9 +/- 0.85 mL/cm H(2)O in the control and protected lobes, respectively. Both groups receiving PMA had similar drops in WBC and neutrophil counts, but the pentoxifylline-protected lobes had preservation of all four compliance measures. PVR increased from 37.8 +/- 1.8 to 118.6 +/- 12.7 cm H(2)O/L/min (p < 0.05) in the injured lobes vs 35.4 +/- 0.5 to 36.3 +/- 2.8 cm H(2)O/L/min and 40.4 +/- 0.04 to 46.7 +/- 2.8 cm H(2)O/L/min (p < 0.05) in the control and protected lobes, respectively. Kf increased < 25% in the protected group but more than tripled in the injured group. Amax/Km dropped from 559 +/- 36 to 441 +/- 33 mL/min (p < 0.05) in the injured lobes vs 507 +/- 14 to 490 +/- 17 mL/min and 609 +/- 34 to 616 +/- 37 mL/min in the control and pentoxifylline-protected lobes, respectively.


CONCLUSIONS
The use of pentoxifylline as a rescue agent prevented the PMA-induced deterioration of lung compliance, vascular integrity, and endothelial metabolic function in this acute lung injury model, despite significant pulmonary neutrophil sequestration.
Creamer
K M
KM
Department of Pediatrics, Tripler Army Medical Center, Honolulu, HI 96859-5000, USA. KCLUVSCS@AOL.com
McCloud
L L
LL
Fisher
L E
LE
Ehrhart
I C
IC
D000818:Animals; D004285:Dogs; D016166:Free Radical Scavengers / Q000494:pharmacology*; D066298:In Vitro Techniques; D007958:Leukocyte Count; D008168:Lung / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D008170:Lung Compliance / Q000187:drug effects; D010431:Pentoxifylline / Q000494:pharmacology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000009:adverse effects*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
D016166:Free Radical Scavengers; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D007703:Peptidyl-Dipeptidase A; D013755:Tetradecanoylphorbol Acetate; D010431:Pentoxifylline